10-Q: Protagonist Advances Key Programs, Reports Q2 Loss

Protagonist Therapeutics submitted an NDA for icotrokinra and reported positive Phase 3 results for rusfertide, despite a net loss for the quarter due to lower collaboration revenue.

Summary

• Protagonist Therapeutics, a biopharmaceutical company, reported a net loss of $46.426 million for the six months ended June 30, 2025, compared to a net income of $176.724 million for the same period in 2024.
• License and collaboration revenue significantly decreased to $33.867 million for the six months ended June 30, 2025, from $259.120 million in the prior year, primarily due to the non-recurrence of a large upfront payment from Takeda in 2024.
• Research and development expenses increased by 8% to $72.929 million for the six months ended June 30, 2025, driven by increased investment in preclinical and drug discovery programs (PN-881, PN-477).
• The company's cash, cash equivalents, and marketable securities stood at $673.0 million as of June 30, 2025, up from $559.2 million at December 31, 2024.
• A New Drug Application (NDA) for icotrokinra for moderate-to-severe plaque psoriasis was submitted to the FDA by J&J Innovative Medicines in July 2025, following positive Phase 3 trial results.
• Rusfertide's Phase 3 VERIFY trial for polycythemia vera met its primary endpoint with 76.9% clinical response, and an NDA filing is expected in the fourth quarter of 2025.
• New development candidates, PN-881 (IL-17 antagonist) and PN-477 (obesity triple agonist), are advancing, with Phase 1 studies anticipated in Q4 2025 and Q2 2026, respectively.

Sentiment

Score: 7

Explanation: While the financial results show a significant net loss and revenue decline compared to the prior year, this is largely due to the non-recurring nature of large collaboration payments in 2024. Operationally, the company has made substantial positive progress with its lead assets: icotrokinra's NDA submission and rusfertide's positive Phase 3 results and upcoming NDA. The pipeline expansion with PN-881 and PN-477 also adds long-term value. The strong cash position provides a solid runway, though future capital raises are anticipated for continued growth.

Positives

• New Drug Application (NDA) for icotrokinra in moderate-to-severe plaque psoriasis submitted to the FDA by J&J Innovative Medicines in July 2025, indicating significant progress towards commercialization.
• Icotrokinra met all primary and co-primary endpoints across four pivotal Phase 3 ICONIC trials, demonstrating significant skin clearance and a favorable safety profile.
• Icotrokinra showed superiority to deucravacitinib in moderate-to-severe plaque psoriasis in ICONIC-ADVANCE 1 & 2 trials.
• Positive topline results from the Phase 2b ANTHEM-UC trial for icotrokinra in ulcerative colitis, meeting the primary endpoint of clinical response in all dose groups.
• Rusfertide's Phase 3 VERIFY trial for polycythemia vera achieved its primary endpoint, with 76.9% of patients achieving clinical response compared to 32.9% for placebo (p<0.0001).
• Rusfertide demonstrated statistically significant improvements in patient-reported outcomes for fatigue and symptom burden in PV patients.
• The company maintains a strong cash position with $673.0 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
• New development candidates PN-881 (IL-17 oral peptide antagonist) and PN-477 (obesity triple agonist) are progressing, expanding the pipeline.

Negatives

• Reported a net loss of $46.426 million for the six months ended June 30, 2025, a significant decline from a net income of $176.724 million in the prior year period.
• License and collaboration revenue decreased by 87% to $33.867 million for the six months ended June 30, 2025, compared to $259.120 million in the same period of 2024, primarily due to the non-recurrence of a large upfront payment from the Takeda collaboration in 2024.
• The company has incurred cumulative net losses of $386.9 million from inception through June 30, 2025, and expects to incur additional losses in the future.
• Research and development expenses increased by $5.7 million, or 8%, for the six months ended June 30, 2025, indicating higher operational costs.

Risks

• The company has incurred significant cumulative net losses and expects to incur additional losses in the future as it continues development and pre-commercialization activities.
• Additional funding may be required to advance the early discovery pipeline and develop/acquire/in-license other product candidates, and such funding may not be available on acceptable terms, if at all.
• Future funding requirements are dependent on the progress, timing, scope, results, and costs of clinical trials, ability to enroll patients, costs of clinical supplies, and success of commercialization.
• Raising additional capital through equity offerings could dilute the ownership interest of existing stockholders, and debt financing could impose restrictive covenants.
• The probability of success for product candidates is affected by numerous factors, including preclinical and clinical data, competition, manufacturing capability, cost of goods, regulatory approvals, market conditions, and commercialization ability.
• Uncertainty and disruption in the global economy and financial markets due to geopolitical instability, high interest rates, and changes in trade policies could materially affect the business and access to credit/financial markets.
• Changes or disruptions at the U.S. Food and Drug Administration (FDA) and other government agencies could impact the business.
• Ongoing military conflicts (e.g., Ukraine and Russia, Middle East) and rising tensions (e.g., China and Taiwan) pose risks.

Future Outlook

The company expects to continue incurring significant research and development expenses and other operational costs, anticipating future losses as it advances rusfertide Phase 3 development through a potential NDA filing and invests in preclinical discovery programs. Revenue in 2025 is expected to reduce significantly compared to 2024 due to the non-recurring nature of large upfront collaboration payments received in the prior year. The company's existing cash, cash equivalents, and marketable securities are projected to fund operations for at least the next twelve months. Future funding requirements will depend on the progress and success of clinical trials, regulatory approvals, commercialization efforts, and potential new collaborations.

Management Comments

• Management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of disclosure controls and procedures and concluded they were effective at the reasonable assurance level as of June 30, 2025.
• The Chief Executive Officer and Chief Financial Officer certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading, and that the financial statements fairly present the financial condition, results of operations, and cash flows.

Industry Context

The biopharmaceutical industry continues to see strong activity in peptide therapeutics, particularly for inflammatory, immunomodulatory, hematology, and metabolic diseases. Protagonist's progress with icotrokinra and rusfertide positions it well in the competitive landscape, especially with an oral IL-23R antagonist and a hepcidin mimetic, which offer differentiated mechanisms or routes of administration compared to existing antibody or injectable therapies. The advancement of new preclinical candidates like PN-881 (IL-17 antagonist) and PN-477 (obesity triple agonist) aligns with major industry trends targeting large and underserved markets, indicating a robust pipeline strategy beyond its lead assets.

Comparison to Industry Standards

• Icotrokinra's Phase 3 ICONIC-ADVANCE 1 & 2 trials demonstrated superiority to deucravacitinib in moderate-to-severe plaque psoriasis. Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor from Bristol Myers Squibb, approved for psoriasis, making icotrokinra's head-to-head superiority a significant competitive advantage for an oral therapy.
• The ICONIC-ASCEND trial, comparing icotrokinra to ustekinumab (Stelara, an injectable biologic from J&J), is a first-ever head-to-head study seeking to demonstrate superiority of an oral pill over an injectable biologic in psoriasis. This directly challenges the established market for biologics and could set a new standard for oral therapies if successful.
• Rusfertide's Phase 3 VERIFY trial results in polycythemia vera (PV) showed a 76.9% clinical response rate, significantly higher than placebo (32.9%). This demonstrates strong efficacy in a rare blood disorder, potentially offering a new standard of care compared to current phlebotomy-dependent management.
• The company's strategy of developing both oral and subcutaneous options for PN-477 (obesity triple agonist) aligns with market demand for flexible and convenient dosing, similar to how companies like Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) are expanding their GLP-1/GIP offerings with various formulations.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Experience a net loss for the period and a significant decrease in collaboration revenue compared to the prior year, but benefit from strong clinical progress of lead assets (icotrokinra NDA submission, rusfertide positive Phase 3 results) which could drive future value. Potential for dilution if future capital raises involve equity.
• **Patients (Plaque Psoriasis):** Potential for a new, convenient oral treatment option (icotrokinra) with demonstrated superiority over an existing oral therapy, offering improved outcomes and quality of life.
• **Patients (Polycythemia Vera):** Potential for a new treatment option (rusfertide) that significantly reduces phlebotomy burden and improves patient-reported symptoms, addressing an unmet medical need in a rare blood disorder.
• **Employees:** Continued investment in research and development, including new preclinical programs, suggests ongoing job stability and growth opportunities within the company's expanding pipeline.
• **Collaboration Partners (JNJ, Takeda):** JNJ benefits from the NDA submission for icotrokinra, moving closer to potential commercialization. Takeda benefits from the positive rusfertide Phase 3 results and assumed regulatory lead, positioning them for a potential NDA filing and future co-commercialization.

Next Steps

• J&J Innovative Medicines to pursue FDA approval for icotrokinra for moderate-to-severe plaque psoriasis.
• J&J Innovative Medicines to prepare comprehensive results from ANTHEM-UC trial for presentation at upcoming medical congresses.
• J&J Innovative Medicines to plan additional clinical studies of icotrokinra in ulcerative colitis and Crohn's disease.
• Continue ongoing Phase 3 clinical trials for icotrokinra in psoriatic arthritis (ICONIC-PsA1, ICONIC-PsA2) and plaque psoriasis (ICONIC-ASCEND).
• Prepare long-term data from the ICONIC development program for presentation at a future medical meeting.
• Submit New Drug Application (NDA) for rusfertide in polycythemia vera to the FDA in the fourth quarter of 2025.
• Continue the THRIVE Phase 2 long-term open-label extension trial for rusfertide.
• Initiate a Phase 1 study for PN-881 (IL-17 oral peptide antagonist) in the fourth quarter of 2025.
• Initiate Phase 1 clinical studies for PN-477 (obesity triple agonist peptide) in the second quarter of 2026.
• Nominate a development candidate for an orally administered hepcidin mimetic or ferroportin inhibitor in the fourth quarter of 2025.
• Evaluate the potential impact of the One Big Beautiful Bill (OBBB) Act on consolidated financial statements.

Key Dates

Recommendation

While the financial results show a significant net loss and revenue decline compared to the prior year, this is primarily due to the non-recurring nature of large upfront collaboration payments in 2024. Operationally, the company has achieved critical milestones: the NDA submission for icotrokinra and positive Phase 3 results for rusfertide, with an NDA expected soon. These clinical successes are highly positive and de-risk the lead assets significantly. The company also has a strong cash position providing a runway for over 12 months. However, the shift to a net loss and the anticipated lower revenue in 2025 compared to 2024, coupled with the ongoing need for future capital, suggest a 'hold' recommendation. Investors should monitor the regulatory approval processes for icotrokinra and rusfertide, as well as the progress of the preclinical pipeline, for future catalysts.

Keywords

Biopharmaceutical, Peptide therapeutics, Inflammatory diseases, Immunomodulatory diseases, Hematology, Blood disorders, Icotrokinra, Rusfertide, Plaque psoriasis, Polycythemia vera, Ulcerative colitis, IL-23R antagonist, Hepcidin mimetic, Phase 3 clinical trials, NDA submission, Drug development, Clinical trials, Biotech, Pharmaceuticals, Orally delivered drugs, Rare diseases, Obesity, GLP-1, GIP, GCG